Furanyl compounds and the use thereof

• US 9,149,527 B2
• Filed: 04/10/2014
• Issued: 10/06/2015
• Est. Priority Date: 06/07/2010
• Status: Active Grant

• Current Assignee: Novomedix LLC
• Original Assignee: Novomedix LLC
• Inventors: Fung, Leah M., Swindlehurst, Cathy A., Chan, Kyle W. H.
• Primary Examiner(s): Rodriguez-Garcia, Valerie
• Application Number:
  US14/250,089
• Publication Number:
  US 20140309297A1
• Time in Patent Office: 544 Days
• US Class Current: 1/1
• CPC Class Codes: A61K 31/341 not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 35/02 specific for leukemia
• CPC Class Codes: A61P 35/04 specific for metastasis
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C07D 307/68 Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen

Abstract

Provided herein are substituted furanyl compounds, pharmaceutical compositions comprising the compounds, methods of their preparation, and methods of their use. The compounds provided herein are useful for the treatment, prevention, and/or amelioration of various disorders, including cancer and proliferative disorders. In one embodiment, the compounds provided herein modulate eIF4E activity. In one embodiment, the compounds provided herein modulate the Hedgehog pathway activity. In one embodiment, the compounds provided herein are used in combination with surgery, radiation therapy, immuno therapy and/or one or more additional anticancer drugs for the treatment, prevention, and/or amelioration of cancer and proliferative disorders.

Claims

1. A method of treating or ameliorating a cancer in a subject, comprising administering to the subject a compound of Formula (I):

2. The method of claim 1, wherein L is S(O)₂.

3. The method of claim 1, wherein L is C(O).

4. The method of claim 1, wherein R₄ is

5. The method of claim 1, wherein R₄ is

6. The method of claim 5, wherein the compound has the structure of Formula (V):

7. The method of claim 1, wherein the compound is:

8. The method of claim 1, wherein the cancer is a breast cancer.

9. The method of claim 1, wherein the cancer is an ovarian cancer.

10. The method of claim 1, wherein the cancer is resistant to conventional therapy.

11. The method of claim 1, wherein the cancer is resistant to vincristine, taxol, cytarabine, doxorubicin, or a combination thereof.

12. The method of claim 8, wherein the breast cancer is a triple negative breast cancer.

13. The method of claim 8, wherein the breast cancer is an ER+ breast cancer.

14. The method of claim 8, wherein the breast cancer is an ER−

breast cancer.